Bayer HealthCare Pharmaceuticals has announced its official U.S. launch. The new company incorporates the former Berlex Inc. into Bayer HealthCare Pharmaceuticals, as part of Bayer's acquisition of Schering AG, Germany, Berlex's former parent company.
Bayer HealthCare Pharmaceuticals Inc., headquartered in Wayne, NJ, is the U.S.-based pharmaceuticals unit of Bayer HealthCare. Bayer HealthCare's pharmaceutical business is dedicated to developing, manufacturing and marketing products that help improve human health, and globally ranks among the top 10 specialty pharmaceutical companies. The global pharmaceutical business employs more than 40,000 people, with approximately 5,500 employees in the United States.
The company's global Oncology and Specialized Therapeutics business units, as well as certain U.S.-based global drug development groups and other business support functions, will be housed in its Montville, N.J. offices. The establishment of Bayer HealthCare Pharmaceuticals is expected to bring an estimated 300 new jobs to New Jersey.
"As the largest single pharmaceutical market in the world, the U.S. offers our organization a tremendous opportunity to strengthen our position in the specialty pharmaceuticals arena," said Reinhard Franzen, president of Bayer HealthCare Pharmaceuticals. "New Jersey is one of the most important centers for the U.S. pharmaceutical industry and offers access to a highly skilled workforce and close proximity to future business partners."
Bayer's combined pharmaceutical portfolio includes product offerings in, and research groups devoted to, Diagnostic Imaging, Hematology/Cardiology, Oncology, Specialized Therapeutics and Women's Healthcare. Leading products in the United States include: